Medical Condition News

RSS

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

The vast majority of pediatricians and family physicians nationally are offering the human papillomavirus (also called HPV) vaccine, though fewer physicians are strongly encouraging it for 11- to 12-year-old girls as recommended by national guidelines, according to a survey in the September issue of Pediatrics, the journal of the American Academy of Pediatrics.

3 Aug 2010

Alphavirus vector induce immune responses in people with advanced cancer: Researchers

There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.

3 Aug 2010

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.

3 Aug 2010

Neuroglobin may protect against Alzheimer's disease: Study

A team of scientists at the University of California, Davis and the University of Auckland has discovered that neuroglobin may protect against Alzheimer's disease by preventing brain neurons from dying in response to natural stress. The team published the results of their study in the April, 2010 issue of Apoptosis.

3 Aug 2010

Percutaneous heart valve replacement may be an alternative for open heart surgery

A newer, less invasive method of heart valve replacement shows promise and may be appropriate for patients who cannot tolerate traditional open heart surgery, but research is needed to understand its potential risks and benefits, according to a new study funded by HHS' Agency for Healthcare Research and Quality.

3 Aug 2010

OECD approves new, non-animal testing guideline for skin irritation

After more than a decade of scientific research and lobbying by animal protection groups, the Organisation for Economic Cooperation and Development (OECD) has approved a new, non-animal testing guideline for skin irritation. The guideline was adopted on July 22 and it is now available for use by companies and governments worldwide.

3 Aug 2010

Research links body weight to glaucoma risk

This month's Ophthalmology journal includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for glaucoma. Also, from researchers at the Tokyo Medical and Dental University, comes the first specific map of how the development of myopic maculopathy, an illness that afflicts many severely nearsighted people, predicts which patients will be most susceptible to vision loss.

3 Aug 2010

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

3 Aug 2010

BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy

BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.

3 Aug 2010

VertiFlex enrolls 150 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 150 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

3 Aug 2010

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

A new UCLA study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status.

2 Aug 2010

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.

2 Aug 2010

NYU PRC receives $3.2M award to establish Comparative Effectiveness Research Program

The NYU Health Promotion and Prevention Research Center at the NYU School of Medicine announced it has received a $3.2 million award from the Centers for Disease Control and Prevention to establish a Comparative Effectiveness Research Program focused on hypertension and colorectal cancer health disparities in African-American men in New York City.

2 Aug 2010

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that preclinical data on three of its pipeline candidates will be highlighted at the XXIII International Complement Workshop taking place August 1-5, 2010, in New York City.

2 Aug 2010

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Scientists have made an important discovery that could lead to new drugs that reduce the severity of blood infections leading to sepsis. Research presented in the August 2010 issue of Journal of Leukocyte Biology shows how interfering with the function of the cell membrane protein called "Programmed Death 1" (PD-1) improves survival in a clinically relevant model of severe infection.

2 Aug 2010

WellDoc DiabetesManager System receives FDA clearance

WellDoc, a healthcare company that develops technology solutions to improve chronic disease management outcomes and reduce healthcare costs, today announced that it has received United States Food and Drug Administration 510(k) clearance to market the WellDoc DiabetesManager System to healthcare providers and their adult patients with type 2 diabetes.

2 Aug 2010

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Ben-Gurion University of the Negev Professor Varda Shoshan-Barmatz has been awarded a three-year, $600,000 grant from the U.S. Leukemia & Lymphoma Society to develop target-specific, anti-cancer drugs.

2 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis. According to the new report entitled Treatment Algorithms in Ulcerative Colitis, surveyed gastroenterologists most often prescribe Humira for ulcerative colitis for patients with loss of response, intolerance or no response to Centocor Ortho Biotech's Remicade.

2 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Medical Condition News

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

Alphavirus vector induce immune responses in people with advanced cancer: Researchers

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

Neuroglobin may protect against Alzheimer's disease: Study

Percutaneous heart valve replacement may be an alternative for open heart surgery

OECD approves new, non-animal testing guideline for skin irritation

Research links body weight to glaucoma risk

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy

VertiFlex enrolls 150 patients in Superion Interspinous Spacer IDE clinical trial

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

NYU PRC receives $3.2M award to establish Comparative Effectiveness Research Program

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

WellDoc DiabetesManager System receives FDA clearance

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News